Giredestrant Outperforms SOC in ER+/HER2- Early Breast Cancer

In an interview with Targeted Oncology at the San Antonio Breast Cancer Symposium (SABCS), Aditya Bardia, MD, MPH, FASCO, discussed the results of the phase 3 lidERA trial (NCT04961996), examining giredestrant (GDC-9545) vs standard-of-care (SOC) endocrine therapy in patients with estrogen receptor (ER)-positive, HER2-negative, medium- and high-risk early breast cancer.

Bardia, a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at the University of California, Los Angeles Health explained that giredestrant significantly improved invasive disease-free survival (IDFS) compared to the SOC. Three-year IDFS rates were 92.4% for giredestrant vs 89.6% for SOC.

Notably, the benefit was consistent across all prespecified subgroups, including premenopausal status and prior chemotherapy. Secondary end points also favored giredestrant, with a 31% reduction in distant recurrence risk (HR, 0.69) and a numerically positive trend in overall survival (OS) (HR, 0.79), though OS data remain immature.